CardioNet (NASDAQ:BEAT), which provides cardiac monitoring, manufacturing, and lab services, has just announced what may prove to be a significant catalyst in the company's development. BEAT with an $82 market cap, operates in the specialty health services industry. People with heart conditions known as arrhythmias need to wear a monitor which translates via information to physicians via wireless sensors any irregularities that would require attention and possibly emergency services. CardioNet has been at the same thing since 2002 when it received FDA approval for its core technology. The company has grown from 3000 initial adopters to over 500,000 users today on a national scale.
While BEAT did receive a national reimbursement code in 2010, which was obviously crucial...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: